Hematología y Hemoterapia

Resultados: 306
Tipo Título / Nombre Autor(es) Año
Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates Martínez López J, Montesinos P, Martínez Sánchez P, Gorrochategui J, Rojas JL, Prino D, et al 2020
Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry Martínez P, Palanques Pastor T, López Lorenzo JL, Cornago Navascués J, Rodríguez Macías G, Cano I, et al 2020
Evolving treatment patterns and outcomes in older patients (?60 years) with AML: changing everything to change nothing? Martínez-Cuadrón D, Serrano J, Gil C, Tormo M, Martínez-Sánchez P, Pérez-Simón JA, et al 2020
Characteristics and treatment strategies of Secondary Acute Myeloid Leukemia Patients: Data from the PETHEMA AML epidemiological registry Martínez-Cuadrón D, Serrano J, Martínez O, Pérez-Simón JA, Gil C ..., Bergua JM, et al 2020
Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL Mehta-Shah N, Chavez JC, Abrisqueta P, Johnson N, Bergua Burgues JM, Grande-García C, et al 2020
Correction to: Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus Montesinos P, Bergua J, Infante J, Esteve J, Guimaraes JE, Sierra J, et al 2020
Antithrombotic treatment in patients with factor VII deficiency: case reports Moriano B, Bermejo N, Rodríguez A, Espina M, Espina M, Ramos L, et al 2020
A novel genetic variant in PTGS1 affects N-glycosylation of cyclooxygenase-1 causing a dominant-negative effect Palma-Barqueros V, Crescente M, de la Morena ME, Chan MV, Almarza E, Revilla N, et al 2020
Nuevo mecanismo de disfunción plaquetaria asociada a sangrado por alteración molecular de PTGS1 que altera la N-glicosilación y función de COX-1 con efecto dominante negativo Palma-Barqueros V, Crescente M, De la Morena-Barrio ME, Chan M, Bohdan N..., Suárez Varela S, et al 2020
Bispecific T cell engager antibodies may contribute to reactivate pre-existing tumor specific T cells Primo D, Pérez Oteyza J, Bergua JM, Hernández Rivas JA, Ruiz E, Vives S, et al 2020